Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 9,445 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacokinetics Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.

NCT06385119
View directory record Official record
Conditions
Healthy Participants
Interventions
Plixorafenib, Cobicistat
Drug
Lead sponsor
Fore Biotherapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 22, 2026, 6:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production

NCT04268953
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Tricaprilin
Drug
Lead sponsor
Cerecin
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 22, 2026, 6:38 AM EDT
Completed Phase 1 Interventional

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia

NCT04155645
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD8233 subcutaneous injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Chula Vista, California • Glendale, California • La Mesa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Oct 22, 2026, 6:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

NCT07205081
View directory record Official record
Conditions
Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
Interventions
ATTO-3712, Placebo
Drug
Lead sponsor
Attovia Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
9
States / cities
Encinitas, California • Fountain Valley, California • Huntington Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 22, 2026, 6:38 AM EDT
Completed Phase 1 Interventional Results available

SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.

NCT02036645
View directory record Official record
Conditions
Mild-Moderate Alzheimer's Disease, Healthy Elderly
Interventions
MEDI1814 for IV injection, MEDI1814 for Subcutaneous Injection, IV Placebo, Placebo for Subcutaneous Injection
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years to 85 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Glendale, California • Long Beach, California • Panorama City, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2019 · Synced Oct 22, 2026, 6:38 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Encaleret in Participants With Autosomal Dominant Hypocalcemia (ADH) Type 1

NCT04581629
View directory record Official record
Conditions
Autosomal Dominant Hypocalcemia (ADH), Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Interventions
Encaleret
Drug
Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Industry
Eligibility
16 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 22, 2026, 6:38 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of MK-6552 and the Effect of Food in Healthy Participants (MK-6552-006)

NCT06567002
View directory record Official record
Conditions
Healthy
Interventions
MK-6552
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 22, 2026, 6:38 AM EDT
Completed Phase 1 Interventional

The Effects of Valproic Acid on Zidovudine Glucuronidation and Pharmacokinetics in HIV-Infected Patients.

NCT00000629
View directory record Official record
Conditions
HIV Infections
Interventions
Valproic acid, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 22, 2026, 6:38 AM EDT
Completed Phase 4 Interventional Results available

Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML

NCT03727750
View directory record Official record
Conditions
ECG, Pharmacokinetics, Safety
Interventions
Gemtuzumab Ozogamicin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Augusta, Georgia • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 22, 2026, 6:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function

NCT00969813
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2010 · Synced Oct 22, 2026, 6:38 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Investigating the Pharmacokinetics and Pharmacodynamics of Recombinant Human Insulin Administered by Dry Powder Inhaler

NCT00426920
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Insulin
Drug
Lead sponsor
QDose Limited
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2007 · Synced Oct 22, 2026, 6:38 AM EDT
Completed Phase 2 Interventional Results available

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.

NCT00603382
View directory record Official record
Conditions
Asthma
Interventions
GW685698X, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
94
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 81 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 22, 2026, 6:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population

NCT05966324
View directory record Official record
Conditions
Hypertension
Interventions
baxdrostat
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 22, 2026, 6:38 AM EDT
Completed Phase 1 Interventional

Study of CPI-100 in Patients With Advanced Tumors

NCT03781362
View directory record Official record
Conditions
Advanced Tumors
Interventions
CPI-100, Capecitabine
Drug
Lead sponsor
Coordination Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Grand Rapids, Michigan • Cleveland, Ohio • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Oct 22, 2026, 6:38 AM EDT
Completed Phase 2 Interventional

Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)

NCT01775462
View directory record Official record
Conditions
X-Linked Hypohidrotic Ectodermal Dysplasia
Interventions
EDI200
Drug
Lead sponsor
Edimer Pharmaceuticals
Industry
Eligibility
48 Hours to 14 Days · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 22, 2026, 6:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of SPY002-091 in Healthy Volunteers

NCT06672718
View directory record Official record
Conditions
Healthy
Interventions
SPY002-091, Placebo
Drug · Other
Lead sponsor
Spyre Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 22, 2026, 6:38 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A

NCT01775618
View directory record Official record
Conditions
Hemophilia A
Interventions
BAY94-9027
Biological
Lead sponsor
Bayer
Industry
Eligibility
Up to 12 Years · Male only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
7
States / cities
Sacramento, California • Pensacola, Florida • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 22, 2026, 6:38 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)

NCT02078960
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Omacetaxine mepesuccinate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Jacksonville, Florida • Atlanta, Georgia • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 22, 2026, 6:38 AM EDT
Completed Phase 1 Interventional

Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies

NCT00448396
View directory record Official record
Conditions
Advanced Malignancies
Interventions
Patupilone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 19, 2009 · Synced Oct 22, 2026, 6:38 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

NCT03945279
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIIB100, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 22, 2026, 6:38 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.

NCT07456046
View directory record Official record
Conditions
KRAS P.G12D
Interventions
D3S-003
Drug
Lead sponsor
D3 Bio (Wuxi) Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
New Haven, Connecticut • Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 22, 2026, 6:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.

NCT04845646
View directory record Official record
Conditions
Healthy, NAFLD
Interventions
ASC41, Itraconazole, Phenytoin
Drug
Lead sponsor
Gannex Pharma Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 22, 2026, 6:38 AM EDT
Completed Not applicable Interventional Results available

Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)

NCT01401023
View directory record Official record
Conditions
Diarrhea, Clostridium Difficile
Interventions
Tigecycline
Drug
Lead sponsor
Gary E. Stein, Pharm.D.
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
East Lansing, Michigan • Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 22, 2026, 6:38 AM EDT
Active, not recruiting Phase 2 Interventional

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

NCT05819359
View directory record Official record
Conditions
Parkinson's Disease
Interventions
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Drug
Lead sponsor
Bial R&D Investments, S.A.
Industry
Eligibility
35 Years to 80 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
43
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 22, 2026, 6:38 AM EDT